Zevra Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZVRA research report →
Range $18 – $35
Price Chart
About the company
Zevra Therapeutics, Inc. , founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States.
- CEO
- Neil F. McFarlane
- IPO
- 2015
- Employees
- 61
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on ZVRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $521.26M
- P/E
- 6.84
- Fwd P/E
- 6.96
- PEG
- 0.06
- P/S
- 3.53
- P/B
- 2.18
- EV/EBITDA
- 4.37
- Div Yield
- 0.00%
- Gross Margin
- 95.19%
- Op Margin
- 31.47%
- Net Margin
- 52.80%
- ROE
- 38.19%
- ROIC
- 14.78%
Latest fiscal year · YoY change
- Revenue
- $106.47M+350.9%
- Gross Profit
- $89.99M+455.7%
- Op Income
- $-4,233,000
- Net Income
- $83.23M+178.9%
- EPS
- $1.40+161.4%
- OCF Growth
- +97.7%
- FCF Growth
- +96.5%
- 52W High
- $15.04
- 52W Low
- $8.01
- 50D MA
- $10.68
- 200D MA
- $10.85
- Beta
- 0.99
- RSI (14)
- 36
- Avg Volume
- 954.53K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Zevra posted 45% year-over-year revenue growth in Q3, driven by MIPLYFFA launch momentum, while outlining a 2027 sNDA path for pediatric expansion and continued confidence in NPC market growth.· November 3, 2026
- Total net revenue rose to $37.8 million, up 45% from Q3 2025, with $34 million from U.S. MIPLYFFA sales.
- MIPLYFFA demand remains broadening: 13 new prescription enrollment forms were received in Q3, bringing cumulative enrollments since launch to 197.
- Management said disease awareness and claims analysis suggest the U.S. NPC market may be larger than the original 300 to 350 diagnosed estimate, with the broader prevalent estimate still around 900.
- The company expects to file an sNDA in Q1 2027 to expand MIPLYFFA labeling to infants under 24 months, following FDA feedback on the pediatric substudy.
- Zevra ended Q3 with $270.9 million in cash, cash equivalents and investments, and said it does not expect meaningful increases in marketing spend next year.
Zevra reported Q3 2026 total net revenue of $37.8 million, up $11.7 million, or 45%, versus $26.1 million in Q3 2025. Revenue consisted of $34 million from MIPLYFFA U.S. net sales, $0.2 million from OLPRUVA, and $3.6 million in net reimbursements from the global EAP. U.S. MIPLYFFA revenue increased 12.6% sequentially from Q2 2026 and 52% year over year. Operating expenses were $24.1 million, up $3.7 million year over year, with R&D at $4.9 million and SG&A at $19.1 million. Net income was $19.2 million, or $0.31 per basic share and $0.26 per diluted share, versus a net loss of $0.5 million, or $0.01 per share, in Q3 2025. Cash, cash equivalents and investments were $270.9 million at September 30, 2026, up about $10.7 million from June 30, 2026. Management did not provide formal next-quarter or full-year revenue guidance; it said it expects to file an sNDA in Q1 2027 for patients under 24 months and continues to expect the CHMP opinion in Q4, with a USPTO patent-term-extension decision now anticipated in 2027.
Neil McFarlane framed Zevra as a purpose-driven rare-disease company focused on disciplined execution and patient impact. He emphasized that MIPLYFFA’s U.S. launch is still early, pointing to rising awareness, newly diagnosed patients, and a larger-than-expected market opportunity. He also highlighted strategic priorities around pediatric label expansion, global access for arimoclomol, and advancing celiprolol with a potential acceleration path.
Justin Renz emphasized the strength of the financial base, citing $37.8 million of Q3 revenue, $24.1 million of operating expenses, and $270.9 million of cash, cash equivalents and investments at quarter end. He noted R&D was $4.9 million and SG&A was $19.1 million, both up year over year largely due to development and commercial infrastructure spending. He said the company is in a strong financial position and, with a modest team expansion next year, does not foresee meaningful increases in marketing spend.
Analysts focused on how much upside remains in MIPLYFFA after a strong launch, whether new enrollments are coming from already diagnosed patients or newly diagnosed ones, and what the under-24-month label expansion could add. Management said the market still appears larger than originally estimated, with a steady flow of newly diagnosed patients and a roughly 50/50 adult-pediatric mix, and said the pediatric expansion is meaningful strategically even though it adds only about 5% to the addressable market. Questions also covered competition and the EMA reexamination; management said additional competition could expand awareness and diagnosis, while remaining confident in the totality of the arimoclomol data and still expecting a CHMP opinion in Q4.
The bull case is that MIPLYFFA is still early in its launch curve, with 197 cumulative enrollments, strong reimbursement, and management seeing a larger patient pool than originally assumed. Zevra also has a substantial cash position, potential pediatric label expansion in 2027, and long-dated IP protection, including Orange Book patents to 2041 and orphan exclusivity through 2031.
The main risks are that the company is still relying heavily on one product and on a rare-disease market that is difficult to size precisely. Management also pointed to regulatory uncertainty in Europe for arimoclomol, a long timeline for the pediatric sNDA and patent-term-extension decisions, and the possibility that the market opportunity may not expand as quickly as hoped despite rising awareness.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.7%
- Shares Outstanding
- 59.50M
- Float Shares
- 53.98M
of shares held by institutions
168 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 5.56M | ▲ 647.06K |
| Blackrock, Inc. | 5.14M | ▲ 26.88K |
| Woodline Partners LP | 4.79M | ▲ 1.33M |
| Vanguard Group Inc | 3.31M | ▲ 221.84K |
| Vanguard Capital Management LLC | 2.63M | ▼ 11.87K |
| State Street Corp | 2.05M | ▲ 368.68K |
| Nantahala Capital Management, LLC | 1.96M | ▲ 165.62K |
| Geode Capital Management, LLC | 1.55M | ▲ 13.96K |
| Morgan Stanley | 1.52M | ▲ 317.16K |
| D. E. Shaw & Co., Inc. | 1.31M | ▲ 460.49K |
| Legal & General Group PLC | 1.20M | ▲ 38.58K |
| Dimensional Fund Advisors LP | 1.12M | ▲ 157.71K |
Held by 190 ETFs
Biggest fund positions in ZVRA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 10, 26 | McFarlane Neil F. | other | 50,000 |
| Oct 12, 26 | McFarlane Neil F. | sell | 20,000 |
| Oct 10, 26 | McFarlane Neil F. | other | 50,000 |
| Aug 14, 26 | Thompson Rahsaan | sell | 42,666 |
| Aug 10, 26 | Watton Corey Michael | other | 12,300 |
| Aug 10, 26 | Watton Corey Michael | other | 12,300 |
| Aug 10, 26 | Watton Corey Michael | sell | 12,300 |
| Jun 21, 26 | Thompson Rahsaan | other | 66,667 |
| Jun 22, 26 | Thompson Rahsaan | sell | 34,557 |
| Jun 21, 26 | Thompson Rahsaan | other | 66,667 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZVRA coverage
Recent articles, reports, and earnings notes.
No research on ZVRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZVRA report →Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
globenewswire.com · Nov 18
Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
globenewswire.com · Nov 13
Wall Street Analysts Believe Zevra Therapeutics (ZVRA) Could Rally 117.86%: Here's is How to Trade
zacks.com · Nov 9
Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates
zacks.com · Nov 3
Zevra Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 3
Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
globenewswire.com · Nov 3
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
globenewswire.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.